Biocad

This phase III trial is investigating whether adding an experimental drug called BCD-248 to daratumumab can improve outcomes for people with multiple myeloma that has returned or become resistant to treatment. The study will compare this new combination against the current standa…

This study tests a new medicine called BCD-281 in people with relapsing-remitting multiple sclerosis (RRMS). The goal is to see if it reduces brain lesions and relapse rates better than the current standard drug. About 292 adults aged 18-55 with mild to moderate disability are be…

This phase 3 trial is testing a single dose of ANB-002, a gene therapy that delivers a working copy of the FIX gene, in 24 adults with hemophilia B. The goal is to see if it can reduce bleeding episodes compared to regular preventive factor IX infusions. Participants will be foll…

This study tests a new drug, BCD-261, in 198 adults with moderate to severe ulcerative colitis who haven't improved with standard treatments. Participants receive one of three doses of BCD-261 or a placebo as an injection. The goal is to see if the drug can reduce inflammation an…

This study tests a new drug called BCD-261 in 204 adults with moderate to severe active Crohn's disease who haven't improved with standard treatments. Participants receive either a low, medium, or high dose of BCD-261 or a placebo by injection. The goal is to see if the drug can …